Navigation Links
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Date:6/4/2009

nce they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

        -- our ability to borrow additional amounts under the loan from Bay
           City Capital, which is subject to the discretion of Bay City
           Capital;
        -- our ability to obtain necessary financing in the near term,
           including amounts necessary to repay the loan from Bay City Capital
           by the September 14, 2009 maturity date (or earlier if certain
           repayment acceleration provisions are triggered);
        -- our ability to control our operating expenses;
        -- our ability to comply with covenants included in the loan from Bay
           City Capital;
        -- our ability to maintain the listing of our common stock on NASDAQ;
        -- our failure to timely recruit and enroll patients for the FDG-PET
           clinical trial, as well as any future clinical trial;
        -- our failure to obtain sufficient data from enrolled patients that
           can be used to evaluate VIA-2291, thereby impairing the validity or
           statistical significance of our clinical trials;
        -- our ability to successfully complete our clinical trials of
           VIA-2291 on expected timetables and the outcomes of such clinical
           trials;
        -- complexities in designing and implementing cardiovascular clinical
           trials using histological examinations, measurement of biomarkers,
           medical imaging and atherosclerotic plaque bioassays;
        -- the results of our clinical trials, including without limitation,
           with respect to the safety and efficacy of VIA-2291;
        -- if the results of
'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... SAN DIEGO , March 26, 2015  BioNano ... the appointment of  Terry Salyer as chief commercial ... building highly effective, worldwide sales teams in life sciences. ... Irys ® System, a genome-mapping platform to assemble ... and investigate structural variations. To date, 32 institutions located ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 ReliantHeart, Inc., ... and Transonic, a supplier of precision transit-time flow measurement ... will greatly improve the efficiency of the HeartAssist5® ... LVAD patients to experience greater mobility and peace of ... the miniature flow board, will draw 1/6th of the ...
(Date:3/25/2015)... Russia,s pharmaceutical market is one of the ... to its absolute size, plus a growing economy and ... from Business Monitor International. The Russian market is set ... pharmaceutical market, with growth estimates around 10-15% annually reaching ... About Green Cross Green Cross ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... Bloodstream- Data Demonstrates Sustained Release and Increased ... Phosphagenics Limited ("Phosphagenics") (ASX: POH; OTCQX: ... preclinical studies related to its patented TPM/oxycodone ... preclinical studies demonstrated that by incorporating TPM/oxycodone ...
... Exiqon Diagnostics, announced today a strategic commercial partnership ... solution provider for oncologists that offers clinically useful ... Exiqon Diagnostics, a leader in individualizing cancer ... EDR(R) Assay) clinical laboratory services, will become a ...
... L.P., a subsidiary of Mylan Inc. (Nasdaq: ... market and distribute EMSAM(R) in the U.S. EMSAM, a ... which was approved by the U.S. Food and Drug ... depressive disorder. EMSAM previously was marketed and distributed by ...
Cached Biology Technology:Phosphagenics Announces Completion of Transdermal Patch Prototypes 2Phosphagenics Announces Completion of Transdermal Patch Prototypes 3Phosphagenics Announces Completion of Transdermal Patch Prototypes 4Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists 2Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists 3Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder 2
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... March 12, 2015 The mascots of the ... Hospital, part of Wake Forest Baptist Medical Center. They ... the 2015 ACC Men,s Basketball Tournament. Young patients enjoyed ... and getting their autographs. Brenner Children,s Hospital ... is the only children,s hospital in northwest ...
(Date:3/11/2015)...   The Sync Project™ today announced ... and harness music to improve health. The platform ... measurements of physiology, enabling the study of the ... populations. It is designed for medical and health ... studies and accelerate the discovery of the clinical ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... into our brain, and new research by University of ... known that fear and other highly emotional experiences lead ... today (Tuesday, June 14) in advance of publication in ... Kaufer and colleagues report a new way for emotions ...
... , This release is available in Spanish ... mixes are a produce section favorite. They offer convenience, selection, ... from the chore of washing and chopping, slicing, or shredding ... time to time, been associated with bagged salad greens. The ...
... to replace lost teeth with titanium dental implants could be ... only at micro level but also at nano level, researchers ... a method that could shorten the healing time for patients. ... the conductivity of the implant allows us to affect the ...
Cached Biology News:Fear boosts activation of young, immature brain cells 2Fear boosts activation of young, immature brain cells 3Scientists pitch in to help keep salad mixes safe to eat 2Healing times for dental implants could be cut 2
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... cleaning agent for removing RNase ... and pipettors. It is ... contamination from microcentrifuge tubes without ... Zap (R) is ...
Mol wt: average mol wt12,360.96 Da by calculation...
... of a series of media originally developed at ... al. for the large scale propagation of cells ... primarily used for the growth and maintenance of ... of viruses in these cell lines. One of ...
Biology Products: